Výsledky vyhledávání

Oral immunotherapy with type V collagen in idiopathic pulmonary fibrosis

Autor: Kevin F. Gibson, Imre Noth, Kevin R. Flaherty, Katia Rothhaar, Michael J. Klemsz, Sarah Frye, Terrence Chew, Naftali Kaminski, Wade Lange, David S. Wilkes

Publikováno v: European Respiratory Journal. 45:1393-1402

Idiopathic pulmonary fibrosis (IPF) is a progressive lung disease with poor prognosis. IPF appears to be heterogeneous in pathobiology with ∼40% of IPF patients found to have elevated levels of circulating antibodies to the autoantigen type V colla

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fc936a981a5640c26972284f47ff0e72
https://doi.org/10.1183/09031936.00105314

Zobrazit plný text záznamu

A Phase One, Open Label, Multi-Dose Study To Evaluate The Safety, Tolerability, And Biologic Effects Of Three Doses Of IW001 In Patients With Idiopathic Pulmonary Fibrosis (IPF)

Autor: Wade Lange, David S. Wilkes, Michael J. Klemsz, Katia Rothhaar, Sarah Frye, Terrence Chew

Publikováno v: C55. INTERSTITIAL LUNG DISEASE: DIAGNOSTIC AND THERAPEUTIC CONSIDERATIONS.

Purpose IW001, an oral solution of Type V collagen (col(V)), is a therapeutic agent in clinical development for IPF by ImmuneWorks. ImmuneWorks scientists believe that lung injury might result in the exposure of a normally hidden protein to the immun

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8de8b3ff1feb37766eb1931530dded10
https://doi.org/10.1164/ajrccm-conference.2012.185.1_meetingabstracts.a4588

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání